Logo

nucleosome diagnostics

VolitionRx Signs on Diagnostic Oncology CRO for Clinical Studies of Cancer, Sepsis Tests

DXOCRO will conduct large-scale clinical utility studies of Volition's Nu.Q NETs and Nu.Q Cancer tests at multiple sites in the US.

VolitionRx Secures $1.5M Loan From Namur Invest Capital Risk

The non-dilutive funding will go toward an early-access program for Volition's Nu.Q nucleosome quantification technology in the US, EU, and UK.

Delfi Diagnostics Nets $100M in Series A Financing, Plans Multi-Cancer Screening Test

The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening.

VolitionRx, 4D Lifetec Partner to Combine Early Cancer Detection Assays

The companies said Tuesday that they are pursuing a clinical trial utilizing their respective liquid biopsy assays on clinical samples from lung cancer patients.

VolitionRx Fine-Tunes Nucleosome Tech to Advance Cancer Dx Pipeline; Eyes COVID-19 Testing

The firm is planning a hybrid approach to clinical translation, including launching some of its own cancer tests and licensing technology to other labs.